ICON teams up with IBM to reduce time and costs of drug development

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ICON, a provider of drug development solutions, said it’s working with IBM to help reduce the time and costs of drug development while also offering patients enhanced quality of care by connecting them to relevant clinical trials. ICON said it will tap Watson’s cognitive computing power to help the process of identifying patients who meet the criteria for a clinical trial, and to analyze protocols to assess trial feasibility and identify optimal trial sites.

Initially, ICON is applying Watson Clinical Trial Matching to its breast, lung, colon and rectal cancer trials.

The solution enables ICON to advise sponsors how many patients match their trial criteria, where they are located and how they will recruit them.

IBM’s Watson Health Cloud will facilitate access to de-identified patient data, including 50 million patient records contained in the data set from Explorys. At the same time, ICON enhances IBM Watson’s capabilities by providing expertise into clinical trial protocols and clinical operations.

More than $1.3 billion is spent on patient recruitment by drug developers each year and yet fewer than 5% of cancer patients participate in a clinical trial. It takes 6-12 months to start up a global phase III drug trial and another 12 months to enroll the required number of patients.

“Recruiting the required number of patients for clinical trials is a constant challenge for our customers and can represent more than 30% of total study costs. ICON’s Chief Operating Officer, Steve Cutler, said in a statement. “By applying IBM Watson to our clinical trials, we have the potential to revolutionize clinical trial feasibility, patient recruitment and study start-up timelines which will help our customers take significant time and cost from their development programs.”

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login